Carteolol Hydrochloride

• CAT Number: A000145
• CAS Number: 51781-21-6
• Molecular Formula: C16H25ClN2O3
• Molecular Weight: 328.83
• Purity: ≥95%
• Synonyms: 51781-21-6; Carteolol HCl; Arteoptic; Mikelan; Abbott-43326
• Target: Neuronal Signaling
• Solubility: Soluble in DMSO
• Storage: Store at -20°C
• InChI: 1S/C16H24N2O3.ClH/c1-16(2,3)17-9-11(19)10-21-14-6-4-5-13-12(14)7-8-15(20)18-13;/h4-6,11,17,19H,7-10H2,1-3H3,(H,18,20);1H
• InChIKey: FYBXRCFPOTXTJF-UHFFFAOYSA-N
• SMILES: CC(C)(C)NCC(COC1=CC=CC2=C1CCC(=O)N2)O.Cl

Carteolol hydrochloride is a beta-adrenergic antagonist used as an anti-arrhythmia agent, an anti-angina agent, an antihypertensive agent, and an antiglaucoma agent. Carteolol Hydrochloride is a nonselective beta-adrenoceptor blocking agent for beta-1 and beta-2 receptors with no membrane-stabilizing activity but moderate intrinsic sympathomimetic effects.

Reference

1: Chikama T, Araie M, Nishida T. [Influence on ocular surface and intraocular
pressure of switching from preservative-containing to preservative-free carteolol
hydrochloride ophthalmic solution]. Nippon Ganka Gakkai Zasshi. 2013
May;117(5):419-26. Japanese. PubMed PMID: 23855234.

2: Yao Q, Yu X, Zheng T, Liu H, Yang Y, Yi P. Spectroscopic studies on the
interaction of carteolol hydrochloride and urea-induced bovine serum albumin.
Spectrochim Acta A Mol Biomol Spectrosc. 2013 Sep;113:447-51. doi:
10.1016/j.saa.2013.04.129. Epub 2013 May 16. PubMed PMID: 23747387.

3: Ishida S, Mochimaru H, Nagai N, Noda K, Ozawa Y. [Effects of carteolol
hydrochloride on experimental choroidal neovascularization]. Nippon Ganka Gakkai
Zasshi. 2011 Apr;115(4):355-61. Japanese. PubMed PMID: 21598603.

4: Kaji Y, Kiuchi T, Oshika T. Carteolol hydrochloride suppresses the generation
of reactive oxygen species and rescues cell death after ultraviolet irradiation
of cultured lens epithelial cells. Open Ophthalmol J. 2010 Oct 12;4:60-5. doi:
10.2174/1874364101004010060. PubMed PMID: 21283534; PubMed Central PMCID:
PMC3031156.

5: Kawase K, Yamamoto T, Muramatsu T, Ono J, Nakajima T, Matsuhisa A, Sugiura T,
Migita M, Ishikawa Y. [Long-acting carteolol hydrochloride 2% ophthalmic solution
phase IV study–investigation of the effectiveness, safety and plasma
concentration]. Nippon Ganka Gakkai Zasshi. 2010 Nov;114(11):976-82. Japanese.
PubMed PMID: 21141077.

6: Nakamoto K, Yasuda N. Effect of carteolol hydrochloride on 24-hour variation
of intraocular pressure in normal-tension glaucoma. Jpn J Ophthalmol. 2010
Mar;54(2):140-3. doi: 10.1007/s10384-009-0780-6. Epub 2010 Apr 18. PubMed PMID:
20401563.

7: Shapiro MK, Gorn R. The possible treatment of migraine with carteolol
hydrochloride. Headache. 1999 Feb;39(2):138-9. PubMed PMID: 18567128.

8: El-Kamel A, Al-Dosari H, Al-Jenoobi F. Environmentally responsive ophthalmic
gel formulation of carteolol hydrochloride. Drug Deliv. 2006 Jan-Feb;13(1):55-9.
PubMed PMID: 16401594.

9: Kuwahara K, Oizumi N, Fujisawa S, Tanito M, Ohira A. Carteolol hydrochloride
protects human corneal epithelial cells from UVB-induced damage in vitro. Cornea.
2005 Mar;24(2):213-20. PubMed PMID: 15725891.

10: Kawai K, Kuwahara K, Oizumi N, Kitagaki H, Fujisawa S. Effects of carteolol
hydrochloride on the in vitro production of LPS-induced proinflammatory cytokines
by murine macrophage. J Ocul Pharmacol Ther. 2004 Jun;20(3):237-45. PubMed PMID:
15279728.